Indian stocks: Visit www.stage2stocks.com →

ABVC BioPharma, Inc.

Stage 4 · Declining · week 11

As of Oct 22, 2026, ABVC BioPharma is in Stage 4, the downtrend phase, now in week 11 (since Aug 11, 2026). It closed at $1.05, 65.0% below its 52-week high and below its 200-day average, which is falling.

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. More about the company

$1.05
+4.70% today
$28.0M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ABVC early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 15w
S4 49w
S2 25w
S4 20w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 15w → S1 10w → S4 4w → S1 1w → S4 49w → S1 5w → S2 25w → S3 4w → S2 2w → S3 11w → S4 20w → S1 9w → S4 10w current
Total tracked: 166 weeks across 13 stage runs.

ABVC among Biotechnology408th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…408ABVCStage 4 · wk 1117−8.2%
vs 52W High
-65.0%
$0.71 lo$2.99 hi
65.0% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 11
1w13w26w
Week 11, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-18.9%
200 DMA: $1.29 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.42x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-8.2%
3M
-9.0%
6M
-8.2%
YTD
-52.2%
1Y
-64.1%
Scan Membership
Breakout Watch
Latest: 2025-04-03
4 appearances in last 60 days. First seen: 2020-09-03.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 11 · Vol 0.42x
2026-10-21S4
Wk 11 · Vol 0.45x
2026-10-20S4
Wk 10 · Vol 0.10x
2026-10-19S4
Wk 10 · Vol 0.23x
2026-10-16S4
Wk 10 · Vol 0.25x
2026-10-15S4
Wk 10 · Vol 0.91x
2026-10-14S4
Wk 10 · Vol 0.48x
2026-10-13S4
Wk 9 · Vol 1.03x
2026-10-12S4
Wk 9 · Vol 0.84x
2026-10-09S4
Wk 9 · Vol 0.36x
2026-10-08S4
Wk 9 · Vol 0.39x
2026-10-07S4
Wk 9 · Vol 0.45x
Moving averages & range
50 DMA
$0.97
200 DMA
$1.29
52W High
$2.99
52W Low
$0.71
5D Low
$0.91
Resistance levels (recent highs)
20d High
$1.13
60d High
$1.16
120d High
$2.02
250d High
$2.99
Next resistance
+7.9%
to 20d High
ROE
-69.9%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 2.6

ABVC BioPharma: quick answers

What stage is ABVC BioPharma in?

As of Oct 22, 2026, ABVC BioPharma (ABVC) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 11, 2026 and is in week 11. What the four stages mean

Is ABVC BioPharma in an uptrend?

No. ABVC BioPharma is in a Stage 4 downtrend. It trades 18.9% below its 200-day average, which is falling.

How far is ABVC BioPharma from its 52-week high?

ABVC BioPharma closed at $1.05 on Oct 22, 2026, 65.0% below its 52-week high of $2.99. Its 52-week low is $0.71.

How has ABVC BioPharma performed over the past year?

As of Oct 22, 2026, ABVC BioPharma is down 64.1% over the past year and down 52.2% so far in 2026.

Which sector and industry is ABVC BioPharma in?

ABVC BioPharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.